Acute lymphoblastic leukaemia in elderly patients: Biological characteristics and therapeutic approaches

Drugs and Aging

Volumn 21, Issue 12, 2004, Pages 779-791

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ASPARAGINASE; BASILIXIMAB; CD19 ANTIGEN; CD20 ANTIBODY; CD22 ANTIGEN; CD33 ANTIGEN; CD52 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; TENIPOSIDE; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CYTOGENETICS; ELDERLY CARE; HUMAN; IMMUNOPHENOTYPING; LEUKEMOGENESIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT PLANNING;

ADULT; AGED; AGING; ANTINEOPLASTIC AGENTS; FEMALE; GERIATRICS; HUMANS; INCIDENCE; LEUKEMIA, LYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; PHENOTYPE; PIPERAZINES; PROGNOSIS; PYRIMIDINES; TREATMENT OUTCOME;

EID: 7044269495     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421120-00003     Document Type: Review

References (69)

1. Kebriaei P, Anastasi J, Larson RA. Acute lymphoblastic leukemia: diagnosis and classification. Best Pract Res Clin Haematol 2002; 15: 597-621
2. Cartwright RA. Epidemiology. In: Whittaker JA, editor. Leukemia. Oxford: Blackwell, 1992
3. Sandier DP, Ross JA. Epidemiology of acute leukemia in children and adults. Semin Oncol 1997; 24: 3-16
4. Hoelzer D, Gokbuget N. New approaches in acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000; 27: 540-59
5. Farhi DC, Rosenthal NS. Acute lymphoblastic leukemia. Clin Lab Med 2000; 20: 17-28
6. Kebriaei P, Larson RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol 2003; 10: 284-9
7. Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia. Semin Oncol 1997; 24: 70-82
8. Taylor PR, Reid MM, Proctor SJ. Acute lymphoblastic leukemia in the elderly. Leuk Lymphoma 1994; 13: 373-80
9. Sorensen JT, Gerald K, Bodensteiner D, et al. Effect of age on survival in acute leukemia: 1950-1990. Cancer 1993; 72: 1602-6
10. Taylor PR, Reid MM, Bown N, et al. Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome. Blood 1992; 80: 1813-7
11. Annino L, Goekbuget N, Delannoy A. Acute lymphoblastic leukemia in the elderly. Hematology J 2002; 3: 219-23
12. Hussein KK, Dahrberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73: 57-63
13. Kantarjian HM, O'Brien S, Smith T, et al. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin dexamethasone (VAD) regimen. Br J Haematol 1994; 88: 94-100
14. Bassan R, Di Bona E, Lerede T, et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Leuk Lymphoma 1996; 22: 295-301
15. Legrand O, Marie JP, Marjanovic Z, et al. Prognostic factors in elderly acute lymphoblastic leukaemia. Br J Haematol 1997; 97: 596-602
16. Thomas X, Olteanu N, Charrin C, et al. Acute lymphoblastic leukemia in the elderly: the Edouard Herriot Hospital experience. Am J Hematol 2001; 67: 73-83
17. Pagano L, Mele L, Casorelli I. Acute lymphoblastic leukemia in the elderly: a twelve year retrospective, single center study. Haematologica 2000; 85: 1327-9
18. Gokbuget N, Hoelzer D, Arnold R, et al. Subtypes and treatment outcome in adult acute lymphoblastic leukemia (ALL) >55 years [abstract]. Hematol J 2001; 1 Suppl. 1: 186
19. Ferrari A, Annino L, Crescenzi S, et al. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia 1995; 9: 1643-7
20. Mandelli F, Annino L, Vegna ML, et al. Treatment of acute lymphoblastic leukemia in the elderly result of the GIMEMAA ALL 0288 >60 years trial. In: Büchner T, Hiddeman W, Wormann B, et al., editors. Acute leukemias VI: prognostic factors and treatment strategies. Berlin: Springer-Verlag, 1997: 688-94
21. Robak T. Compared to traditional protocols, newer induction schedules have limited benefits for older people with acute myeloid leukemia. Evid Based Oncol 2002; 3: 77-80
22. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-14
23. Nagura E, Minami S, Nagata K, et al. Analysis of elderly patients aged 60 years old or over with acute lymphoblastic leukemia. Nippon Ronen Igakkai Zasshi 1999; 36: 52-8
24. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD a dose-intensive regimen in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-61
25. Robak T, Szmigielska-Kap A, Wrzesien-Kus A, et al. Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience. Ann Hematol 2003; 83: 225-31
26. Spath-Schwalbe E, Heil G, Heimpel H. Acute lymphoblastic leukemia in patients over 59 years of age: experience in a single center over a 10 year period. Ann Hematol 1994; 69: 291-6
27. Yenerel MN, Atamer T, Yavuz AS, et al. Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single center study. Ann Hematol 2002; 81: 498-503
28. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357-66
29. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000; 36: 263-73
30. Secker-Walker LM, Prentice HG, Durrant J. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukemia Working Party. Br J Hematol 1997; 96: 601-10
31. Weztler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukaemia Group B experience. Blood 1999; 93: 3983-93
32. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536-43
33. The Groupe Francais de Cytogenetique Hematologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996; 87: 3135-42
34. Delannoy A, Cazin B, Thomas X, et al. Treatment of acute lymphoblastic leukemia in the elderly: an evaluation of vindesine during induction and of interferon alpha given as a single agent after complete remission. Leuk Lymphoma 2002; 43: 75-81
35. Offidani M, Corvatta L, Centurioni R, et al. High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia. Hematology J 2003; 4: 47-53
36. Gokbuget N, Hoelzer D. Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 2002; 6: 114-41
37. Delannoy A, Sebban C, Cony-Makhoul P, et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy: a multicentric prospective study in forty patients. Leukemia 1997; 11: 1429-34
38. Imbach P, Fuchs A, Berchtold W, et al. Boys but not girls with T-lineage acute lymphocytic leukemia (ALL) are different from children with B-progenitor ALL: population based data results of initial prognostic factors and long-term event-free survival. Swiss Pediatric Oncology Group. J Pediatr Hematol Oncol 1995; 17: 346-9
39. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98: 1337-54
40. Delannoy A, Ferrant A, Bosly A. Acute lymphoblastic leukemia in the elderly. Eur J Haematol 1990; 45: 90-3
41. Pagano L, Mele L, Trage G, et al. The treatment of acute lymphoblastic leukemia in the elderly. Leuk Lymphoma 2004; 45: 117-23
42. Elison RR, Mick R, Cuttner J, et al. The effect of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 1991;9:2002-15
43. Virgilio JF, Moscinski LC, Ballerter OF, et al. Acute lymphocytic leukemia ALL in elderly patients. Hematol Oncol 1993; 11: 121-6
44. Cohen J. Pharmacokinetic changes in aging. Am J Med 1986; 80 Suppl. 5A: 31-8
45. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1: 31-6
46. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-42
47. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome positive acute lymphoid leukemias. Blood 2002; 100: 1965-71
48. Ottmann OG, Wassmann B. Imatinib in the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Best Pract Res CHn Haematol 2002; 15: 757-69
49. Ottmann OG, Wassmann B, Gokbuget N, et al. A randomized trial of imatinib versus chemotherapy induction followed by concurrent imatinib and chemotherapy as first-line treatment in elderly patients with de novo Philadelphia-positive acute lymphoblastic leukemia [abstract no. 791]. Blood 2003; 102: 226a
50. Thomas DA, Cortes J, Kanarjian HM. New agents in the treatment of acute lymphocytic leukaemia. Best Pract Res Clin Haematol 2002; 15: 771-90
51. Krishna R, Webb MS, St Onge G, et al. Liposomal and nonliposomal drug pharmacokinetics after administration liposome: encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 2001; 298: 1206-12
52. Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 2000; 11: 69-72
53. Cortes J, O'Brien S, Estey E, et al. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 1999; 17: 81-7
54. Asselin BL. The three asparaginases: comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999; 457: 621-9
55. Robak T. Monoclonal antibodies in the treatment of lymphoid leukemias. Leuk Lymphoma 2004; 45: 205-19
56. Gokbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004; 82; 201-5
57. Ozsahin H, Fluss J, McLin V, et al. Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission. Med Pediatr Oncol 2003; 38: 300-1
58. Jandula BM, Nomdedeu J, Martin P, et al. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2001; 77: 225-7
59. Kolitz JE, O'Mara V, Willemze R, et al. Treatment of acute lymphoblastic leukemia (ALL) with Campath-1H: initial observations [abstract]. Blood 1994; 84: 1191a
60. Dyer MJ, Hale G, Hayhoe FG, et al. Effect of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431-9
61. Avivi I, Rowe JM, Goldstone AH. Stem cell transplantation in adult ALL patients. Best Pract Res Clin Haematol 2002; 15: 653-74
62. Massenkeil G, Nagy M, Lawang M, et al. Reduced intensity conditioning and prophylactic DLS can cure patients with high risk acute leukemias if complete donor chimerism can be achieved. Bone Marrow Transplant 2003; 31: 339-45
63. Giralt S, Anagnastopoulos A, Shahjahanan M, et al. Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes. Semin Hematol 2002; 39: 57-26
64. Saris AH, Phan A, Duvic M, et al. Trimetrexate in relapsed T-cell lymphoma with skin involvement. J Clin Oncol 2002; 20: 2876-80
65. Jones RJ, Sharkis SJ, Miller CB, et al. Bryostatin I, a unique biological response modifier: antileukemic activity in vitro. Blood 1990; 75: 1319-23
66. Wall NR, Mohammad RM, Reddy KB, et al. Bryostatin I induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic cell line, Reh. Int J Mol Med 2000; 5: 165-71
67. Thomas DA, Giles FJ, Cortes J, et al. Antiangiogenic therapy in leukemia. Acta Haematol 2001; 106: 190-207
68. Richardson PG, Berenson J, Irwin D, et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract no. 3223]. Blood 2001; 98: 774a
69. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetics study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812-23